Congratulations to NEALS Co-Chair Dr. Timothy Miller, winner of the 2018 Sheila Essey Award!
Trial News & Events
NEALS has established various subcommittees focused on advancing ALS research and patient care. In an effort to keep our members and subscribers informed about what these focus groups are working on, NEALS will distribute a semi-annual update on committee activities.
The CRLI is a two-day program dedicated to educating attendees on clinical research and therapy development and empowering this group to be even more effective research advocates. Local patients, caregivers, surviving spouses and family, and patient-caregiver pairs are encouraged to apply by May 15, 2018.
Summary recommendations from the NEALS bulbar subcommittee symposium.
FORTITUDE-ALS is a clinical trial of an investigational oral drug for the treatment of amyotrophic lateral sclerosis (ALS). This clinical trial is now enrolling participants in both the United States and Canada.
This guidance document is being distributed for comment purposes only. The purpose of this guidance is to assist sponsors in the clinical development of drugs for the treatment of amyotrophic lateral sclerosis (ALS). Specifically, this guidance addresses the Food and Drug Administration’s (FDA’s) current thinking regarding the clinical development program and clinical trial designs for drugs to support an indication for the treatment of ALS.
Of the 200-plus posters presented during the event, over 58 were submitted by NEALS members. A number of NEALS members also chaired the daily sessions, and even more presented during the meeting.
This study is designed to investigate whether there are risk factors for the development of problems with thinking, behavior and mood in Persons with Amyotrophic Lateral Sclerosis (PALS), and whether these problems affect their caregivers (e.g., spouse, adult child).
Calling all individuals with ALS and caregivers: We need your help!
Take a survey to help guide drug development for ALS
The Dominant Inherited ALS (DIALS) Network research study is recruiting participants who do not have any neurological symptoms, but who have a first-degree relative with ALS caused by a mutation in the C9orf72 or SOD1 gene. The purpose of the research study is to study a population at risk for developing ALS.